Vanguard Group’s NexImmune, Inc. Common Stock NEXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-12,010
| Closed | -$33.1K | – | 4445 |
|
|
2024
Q2 | $33.1K | Hold |
12,010
| – | – | ﹤0.01% | 4320 |
|
|
2024
Q1 | $67.4K | Buy |
+12,010
| New | +$92.5K | ﹤0.01% | 4280 |
|
|
2023
Q4 | – | Sell |
-3,893
| Closed | -$20.4K | – | 4520 |
|
|
2023
Q3 | $20.4K | Hold |
3,893
| – | – | ﹤0.01% | 4497 |
|
|
2023
Q2 | $27.4K | Sell |
3,893
-15,066
| -79% | -$130K | ﹤0.01% | 4503 |
|
|
2023
Q1 | $180K | Hold |
18,959
| – | – | ﹤0.01% | 4335 |
|
|
2022
Q4 | $115K | Hold |
18,959
| – | – | ﹤0.01% | 4376 |
|
|
2022
Q3 | $263K | Buy |
18,959
+1,082
| +6% | +$31.7K | ﹤0.01% | 4377 |
|
|
2022
Q2 | $720K | Buy |
17,877
+1,467
| +9% | +$90.8K | ﹤0.01% | 4188 |
|
|
2022
Q1 | $1.73M | Sell |
16,410
-10,889
| -40% | -$800K | ﹤0.01% | 4015 |
|
|
2021
Q4 | $3.15M | Buy |
27,299
+105
| +0.4% | +$25.2K | ﹤0.01% | 3857 |
|
|
2021
Q3 | $10.3M | Buy |
27,194
+12,743
| +88% | +$4.27M | ﹤0.01% | 3223 |
|
|
2021
Q2 | $5.9M | Buy |
14,451
+6,201
| +75% | +$2.86M | ﹤0.01% | 3509 |
|
|
2021
Q1 | $3.94M | Buy |
+8,250
| New | +$4.49M | ﹤0.01% | 3652 |
|
Other funds holding NEXI
Vanguard Group's NEXI Position: Q3 2024 in Review
Vanguard Group sold out of NexImmune, Inc. Common Stock (NEXI) in Q3 2024, closing a stake of 12,010 shares — an estimated $33.1K sold.
Vanguard Group first reported a position in NEXI in Q1 2021 and held it in 13 quarters. The position peaked at $10.3M in Q3 2021. 1 fund tracked by Wall St. Rank holds NEXI as of Q3 2024.
- Vanguard Group reported no remaining NexImmune, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Vanguard Group sold 12,010 NexImmune, Inc. Common Stock shares in Q3 2024, an estimated $33.1K.
- Vanguard Group first reported a position in NexImmune, Inc. Common Stock in Q1 2021 and held it in 13 quarters.
- Vanguard Group's NexImmune, Inc. Common Stock position peaked at $10.3M in Q3 2021.
- 1 fund tracked by Wall St. Rank held NexImmune, Inc. Common Stock as of Q3 2024.
Based on Vanguard Group's 13F filing for Q3 2024, filed 13 Nov 2024.